NCT03770845

Brief Summary

In recent years nutritional status assumed increasing importance in the evaluation of chronic respiratory diseases, considering that their clinical course is often characterized by a progressive loss of weight and reduction of muscle mass.In regards to Idiopathic Pulmonary Fibrosis (IPF), to date there are no studies that fully assessed the nutritional status of patients, nor the impact of the introduction of specific anti-fibrotic agents on the nutritional status of these patients. Aim of this study is to assess the nutritional status of patients with IPF at the time of diagnosis and the impact of the introduction of specific anti-fibrotic agents, pirfenidone or nintedanib, on the nutritional status itself.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Dec 2018

Typical duration for all trials

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 6, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

December 10, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

December 10, 2018

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2021

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2021

Completed
Last Updated

September 29, 2021

Status Verified

September 1, 2021

Enrollment Period

2.6 years

First QC Date

December 6, 2018

Last Update Submit

September 28, 2021

Conditions

Keywords

nutritional statusvitamin D

Outcome Measures

Primary Outcomes (8)

  • BMI (body mass index)

    kg/m2

    baseline (IPF diagnosis)

  • FFMI (fat free mass index)

    kg/m2

    baseline (IPF diagnosis)

  • SMI (skeletal muscle mass index)

    kg/m2

    baseline (IPF diagnosis)

  • BFMI (body fat mass index)

    kg/m2

    baseline (IPF diagnosis)

  • Hand Grip

    kg

    baseline (IPF diagnosis)

  • Abdominal circumference

    cm

    baseline (IPF diagnosis)

  • Malnutrition Universal Screening Tool (MUST) Screening Tool (MUST)

    questionnaire score: score 0 = low risk of malnutrition; score 1 = medium risk of malnutrition; score equal or higher than 2 = high risk of malnutrition

    baseline (IPF diagnosis)

  • Mini Nutritional Assessment (MNA)

    questionnaire score (maximum score 30): total score \> 23.5 = normal nutritional status; total score \< 23.5 = inadequate nutritional status

    baseline (IPF diagnosis)

Secondary Outcomes (10)

  • BMI (body mass index)

    6 months after baseline

  • FFMI (fat free mass index)

    6 months after baseline

  • SMI (skeletal muscle mass index)

    6 months after baseline

  • BFMI (body fat mass index)

    6 months after baseline

  • Hand Grip

    6 months after baseline

  • +5 more secondary outcomes

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with a diagnosis of mild to moderate Idiopathic Pulmonary Fibrosis

You may qualify if:

  • age greater than or equal to 18 years;
  • diagnosis of IPF according to the ATS / ERS 2011 guidelines with multidisciplinary discussion

You may not qualify if:

  • severe renal failure, defined as a GFR (glomerular filtration rate) lower than 30ml / min;
  • NYHA class IV;
  • severe liver failure, defined as Child-Pugh score class C;
  • active solid or haematological neoplasms;
  • having already received (currently or in the past) therapy with pirfenidone or nintedanib;
  • inability to walk without help;
  • need for oxygen therapy at rest;
  • participation in other interventional experimental protocols with use of a medicinal product.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

INRCA Casatenovo

Casatenovo, Lecco, Italy

Location

San Gerardo Hospital

Monza, MB, 20900, Italy

Location

G. Salvini Hospital

Garbagnate Milanese, Milano, Italy

Location

Ospedale di Circolo

Busto Arsizio, Varese, Italy

Location

Ospedale SS. Annunziata

Chieti, Italy

Location

San Martino Hospital

Genova, Italy

Location

San Giuseppe Hospital

Milan, Italy

Location

San Paolo and San Carlo Hospital

Milan, Italy

Location

Ospedale Maggiore Novara

Novara, Italy

Location

MeSH Terms

Conditions

Idiopathic Pulmonary Fibrosis

Condition Hierarchy (Ancestors)

Pulmonary FibrosisLung Diseases, InterstitialLung DiseasesRespiratory Tract Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

December 6, 2018

First Posted

December 10, 2018

Study Start

December 10, 2018

Primary Completion

June 30, 2021

Study Completion

September 1, 2021

Last Updated

September 29, 2021

Record last verified: 2021-09

Data Sharing

IPD Sharing
Will not share

Locations